News Release

• 4.20, 2010

  UMN Pharma Confirms Immunogenicity and Safety of Avian Influenza A (H5N1) Vaccine Manufactured from Cell-Culture, UMN-0501 in Phase II Clinical Trial

• 4.16, 2010

  API and UMN Pharma Announce Formulation Process Collaboration

• 1.26, 2010

  IHI Corporation and UMN Pharma Announce Manufacturing Collaboration

• 10.05, 2009

  UMN Pharma initiates phase II clinical trial for avian influenza A (H5N1) vaccine manufactured from cell-culture, UMN-0501.

• 6.29, 2009

  Protein Sciences Corporation signs a contract which amounts to about 147 million dollars with U.S. Department of Health and Human Services for new way to make flu vaccine.

Archive